Pfizer announced that the companies have submitted an application to the FDA for emergency use authorisation (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-microgram dose in the three-dose primary series for children 6 months through 4 years of age.
Novartis confirmed plans for the 100% spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to commence on October 4, 2023
Pfizer and BioNTech SE announced they have completed a submission to the FDA requesting Emergency Use Authorization (EUA) of a 10-micrograms booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age
Roche announced that the FDA has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours greater than 4 cm or node positive), as detected by an FDA-approved test
Pfizer Inc. and BioNTech SE announced they have completed a submission to the FDA requesting Emergency Use Authorization (EUA) of a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.
Celgene International S�rl,has announced that statistical significance was achieved for the primary endpoint of ACR 20 at week 16 for...
Genentech, a member of the Roche Group announced positive interim results from the Phase III HAVEN 4 study evaluating Hemlibra...
ObsEva SA announced that the Phase III clinical trial results from its European confirmatory study of nolasiban (IMPLANT 4) in...